RNA interference in the clinic: challenges and future directions
暂无分享,去创建一个
George A. Calin | Robert L. Coleman | Gabriel Lopez-Berestein | G. Calin | A. Sood | R. Coleman | G. Lopez-Berestein | C. Pecot | Anil K. Sood | Chad V. Pecot
[1] J. M. Thomson,et al. Argonaute2 Is the Catalytic Engine of Mammalian RNAi , 2004, Science.
[2] T. Tuschl,et al. Mechanisms of gene silencing by double-stranded RNA , 2004, Nature.
[3] Anil K Sood,et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.
[4] T. Tuschl,et al. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. , 2004, Molecular cell.
[5] Y. Omidi,et al. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. , 2005, Current drug delivery.
[6] Marion Jurk,et al. Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses1 , 2008, The Journal of Immunology.
[7] F. He,et al. Cationic lipids enhance siRNA-mediated interferon response in mice. , 2005, Biochemical and biophysical research communications.
[8] D. Haber,et al. Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites , 2008, Proceedings of the National Academy of Sciences.
[9] M. Stoffel,et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.
[10] Martin L. Miller,et al. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs , 2009, Nature Biotechnology.
[11] Hiroshi Maeda,et al. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.
[12] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[13] V. Kim,et al. Regulating the Regulators: Posttranslational Modifications of RNA Silencing Factors , 2009, Cell.
[14] Jan-Fang Cheng,et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.
[15] Mauro Ferrari,et al. Mathematical modeling of cancer progression and response to chemotherapy , 2006, Expert review of anticancer therapy.
[16] A. Judge,et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.
[17] S. Skinner,et al. Microvascular architecture of experimental colon tumors in the rat. , 1990, Cancer research.
[18] Mauro Ferrari,et al. Design maps for nanoparticles targeting the diseased microvasculature. , 2008, Biomaterials.
[19] Jeong Won Lee,et al. Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles , 2010, Clinical Cancer Research.
[20] R. Vandenbroucke,et al. Maintaining the silence: reflections on long-term RNAi , 2008, Drug Discovery Today.
[21] Suzie H Pun,et al. Extracellular barriers to in Vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver. , 2008, Bioconjugate chemistry.
[22] L. Perlemuter. [From theory to practice]. , 1997, Soins. Psychiatrie.
[23] M Ferrari,et al. The receptor-mediated endocytosis of nonspherical particles. , 2008, Biophysical journal.
[24] J. Geddes,et al. What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.
[25] Mauro Ferrari,et al. Enabling individualized therapy through nanotechnology. , 2010, Pharmacological research.
[26] Domenico Catalano,et al. MitoDrome: a database of Drosophila melanogaster nuclear genes encoding proteins targeted to the mitochondrion , 2003, Nucleic Acids Res..
[27] F. Liu,et al. “New”‐clear functions of PDK1: Beyond a master kinase? , 2005, Journal of cellular biochemistry.
[28] Dipali G. Sashital,et al. Structural insights into RNA interference. , 2010, Current opinion in structural biology.
[29] P. Linsley,et al. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.
[30] R. Duncan. The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.
[31] Eva Harth,et al. Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. , 2010, Cancer research.
[32] John J. Rossi,et al. Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.
[33] Mauro Ferrari,et al. Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.
[34] C. Echeverri,et al. RNAi and iTRAQ reagents united: targeted quantitation of siRNA-mediated protein silencing in human cells , 2009, Analytical and bioanalytical chemistry.
[35] A. Zychlinsky,et al. Neutrophil Extracellular Traps Kill Bacteria , 2004, Science.
[36] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[37] Helmut Friess,et al. Pancreatic cancer microenvironment , 2007, International journal of cancer.
[38] Mark E. Davis,et al. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging , 2006, Nucleic acids research.
[39] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[40] M. Ferrari,et al. The Effective Dispersion of Nanovectors Within the Tumor Microvasculature , 2006, Annals of Biomedical Engineering.
[41] R. Bast,et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. , 2010, Cancer cell.
[42] G. Calin,et al. Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.
[43] V. Kim. MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.
[44] Qi Zhou,et al. Chemically Modified Short Interfering Hybrids (siHYBRIDS): Nanoimmunoliposome Delivery In Vitro and In Vivo for RNAi of HER-2 , 2006, Nucleosides, nucleotides & nucleic acids.
[45] P. Kesharwani,et al. Dendrimer toxicity: Let's meet the challenge. , 2010, International journal of pharmaceutics.
[46] T. Rana,et al. Illuminating the silence: understanding the structure and function of small RNAs , 2007, Nature Reviews Molecular Cell Biology.
[47] T. Park,et al. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[48] Mauro Ferrari,et al. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. , 2010, Trends in biotechnology.
[49] L. Kwak,et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] P. Zamore,et al. Kinetic analysis of the RNAi enzyme complex , 2004, Nature Structural &Molecular Biology.
[51] Matthias John,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.
[52] Henning Urlaub,et al. Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi , 2002, Cell.
[53] Theresa A. Storm,et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.
[54] R. Langer,et al. Lipid‐based nanotherapeutics for siRNA delivery , 2010, Journal of internal medicine.
[55] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[56] S. Lim,et al. FERM control of FAK function: Implications for cancer therapy , 2008, Cell cycle.
[57] Yin Zhang,et al. In Vivo Imaging of RNA Interference , 2010, Journal of Nuclear Medicine.
[58] A. Tari,et al. Cellular Pharmacology of P-ethoxy Antisense Oligonucleotides Targeted to Bcl-2 in a Follicular Lymphoma Cell Line , 2003, Leukemia & lymphoma.
[59] A. Judge,et al. siRNA and innate immunity. , 2009, Oligonucleotides.
[60] Joshua T. Burdick,et al. Common genetic variants account for differences in gene expression among ethnic groups , 2007, Nature Genetics.
[61] Shan Jiang,et al. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. , 2007, Biomaterials.
[62] Shizuo Akira,et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.
[63] Hyunsoo Kim,et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. , 2010, Cancer research.
[64] P. Thall,et al. Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs , 2004, Biometrics.
[65] Justine R. Smith,et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.
[66] D. Balding,et al. HLA Sequence Polymorphism and the Origin of Humans , 2006 .
[67] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.
[68] Vishnu Swarup,et al. Circulating (cell‐free) nucleic acids – A promising, non‐invasive tool for early detection of several human diseases , 2007, FEBS letters.
[69] T. Ochiya,et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[70] A. J. Tavares,et al. Quantum dots as contrast agents for in vivo tumor imaging: progress and issues , 2011, Analytical and bioanalytical chemistry.
[71] T. Park,et al. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. , 2006, Bioconjugate chemistry.
[72] A. Klippel,et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. , 2003, Nucleic acids research.
[73] K. Czaplinski,et al. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. , 2004, RNA.
[74] P. Opolon,et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. , 2006, Human gene therapy.
[75] Parag Aggarwal,et al. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.
[76] K. Baggerly,et al. Dual targeting of EphA2 and FAK in ovarian carcinoma , 2009, Cancer biology & therapy.
[77] G. Hannon,et al. Unlocking the potential of the human genome with RNA interference , 2004, Nature.
[78] M. Hung,et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. , 2008, Cancer cell.
[79] D. Dykxhoorn,et al. Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.
[80] L. Lim,et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.
[81] Rakesh K. Jain,et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.
[82] Jürgen Groll,et al. Phagocytosis independent extracellular nanoparticle clearance by human immune cells. , 2010, Nano letters.
[83] S. Grinstein,et al. The Tangled Webs That Neutrophils Weave , 2004, Science.
[84] Anne Gatignol,et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC , 2007, Nucleic acids research.
[85] A. Sood,et al. The dicey role of Dicer: implications for RNAi therapy. , 2010, Cancer research.
[86] S. Aaronson,et al. Implications for Cancer Therapy , 2003 .
[87] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[88] Robert Langer,et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.
[89] T. Rana,et al. Translation Repression in Human Cells by MicroRNA-Induced Gene Silencing Requires RCK/p54 , 2006, PLoS biology.
[90] Y. Rojanasakul,et al. Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes , 2000, Pharmaceutical Research.
[91] Mark E. Davis,et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.
[92] Kathryn A. Whitehead,et al. Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.
[93] C. Burge,et al. The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution , 2005, Science.
[94] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[95] Mauro Ferrari,et al. The mathematical engines of nanomedicine. , 2008, Small.
[96] S. Pun,et al. 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. , 2008, Bioconjugate chemistry.
[97] L. Lim,et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. , 2006, RNA.
[98] H. Bonnefoi,et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[99] B. Li,et al. Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.
[100] M. Estévez,et al. Nanoparticle-aptamer conjugates for cancer cell targeting and detection. , 2010, Methods in molecular biology.
[101] A. C. Hunter. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. , 2006, Advanced drug delivery reviews.
[102] H. Kawachi,et al. Chemically modified siRNA prolonged RNA interference in renal disease. , 2007, Biochemical and biophysical research communications.
[103] M. Manoharan,et al. RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.